MedPath

KOREA UNITED PHARM. INC.

KOREA UNITED PHARM. INC. logo
🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

16

Active:0
Completed:9

Trial Phases

4 Phases

Phase 1:11
Phase 2:1
Phase 3:2
+1 more phases

Drug Approvals

53

PHILIPPINES:53

Drug Approvals

Livesil

Approval Date
Jul 14, 2025
PHILIPPINES

Kalomin S

Approval Date
Jul 14, 2025
PHILIPPINES

Omnihexol

Approval Date
Jul 14, 2025
PHILIPPINES

Aekovan

Approval Date
Jul 14, 2025
PHILIPPINES

Utoral

Approval Date
Jul 14, 2025
PHILIPPINES

Carbotinol

Approval Date
Jul 14, 2025
PHILIPPINES

UNITAXEL

Approval Date
Jul 14, 2025
PHILIPPINES

Carbotinol

Approval Date
Jul 14, 2025
PHILIPPINES

Emodan

Approval Date
Jul 14, 2025
PHILIPPINES

Herpex

Approval Date
Jul 14, 2025
PHILIPPINES
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials

Phase 1
11 (68.8%)
Phase 3
2 (12.5%)
Phase 4
2 (12.5%)
Phase 2
1 (6.3%)

Drug-drug Interaction Study Between UIC201603, and UIC201604

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: UIC201603 and co-administration of UIC201603 and UIC201604
Drug: UIC201604 and co-administration of UIC201603 and UIC201604
First Posted Date
2024-08-23
Last Posted Date
2024-08-23
Lead Sponsor
Korea United Pharm. Inc.
Target Recruit Count
57
Registration Number
NCT06568133
Locations
🇰🇷

Chungnam National University Hospital, Daejeon, Korea, Republic of

A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201

Phase 1
Not yet recruiting
Conditions
Gastro-Intestinal Disorder
Interventions
Drug: UIC202201
First Posted Date
2024-05-01
Last Posted Date
2024-05-01
Lead Sponsor
Korea United Pharm. Inc.
Target Recruit Count
66
Registration Number
NCT06393881
Locations
🇰🇷

Chungbuk national university hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

A Clinical Study to Evaluate the Safety and the Pharmacokinetics of UI068 in Healthy Adult Volunteers Under Fed Conditions

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: administration of UI068
Drug: administration of UIC202205, UIC202206
First Posted Date
2023-11-21
Last Posted Date
2023-11-21
Lead Sponsor
Korea United Pharm. Inc.
Target Recruit Count
35
Registration Number
NCT06141590
Locations
🇰🇷

H plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of

A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects

Phase 1
Completed
Conditions
GERD
Interventions
Drug: UIC202201
First Posted Date
2023-11-21
Last Posted Date
2023-11-21
Lead Sponsor
Korea United Pharm. Inc.
Target Recruit Count
8
Registration Number
NCT06141577
Locations
🇰🇷

Chungbuk national university hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects

Phase 1
Completed
Conditions
GERD
Interventions
Drug: administration of UI058
Drug: administration of UIC202004
First Posted Date
2022-03-16
Last Posted Date
2024-07-03
Lead Sponsor
Korea United Pharm. Inc.
Target Recruit Count
41
Registration Number
NCT05282914
Locations
🇰🇷

Chungbuk national university hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.